Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 15.4% on Wednesday . The stock traded as high as C$0.24 and last traded at C$0.23. 501,343 shares traded hands during trading, a decline of 18% from the average session volume of 612,724 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The firm has a 50-day moving average price of C$0.10 and a 200-day moving average price of C$0.08. The stock has a market cap of C$27.01 million, a PE ratio of -15.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
